JP7034162B2 - インフルエンザウイルス複製の阻害剤及びその使用 - Google Patents

インフルエンザウイルス複製の阻害剤及びその使用 Download PDF

Info

Publication number
JP7034162B2
JP7034162B2 JP2019533095A JP2019533095A JP7034162B2 JP 7034162 B2 JP7034162 B2 JP 7034162B2 JP 2019533095 A JP2019533095 A JP 2019533095A JP 2019533095 A JP2019533095 A JP 2019533095A JP 7034162 B2 JP7034162 B2 JP 7034162B2
Authority
JP
Japan
Prior art keywords
alkylene
membered
alkyl
heterocyclyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019533095A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513415A (ja
JP2020513415A5 (enExample
Inventor
タン、シャンフア
レン、キンユン
イン、ジュンジュン
イ、カイ
レイ、イボ
ワン、エジュン
ジャン、インジュン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of JP2020513415A publication Critical patent/JP2020513415A/ja
Publication of JP2020513415A5 publication Critical patent/JP2020513415A5/ja
Application granted granted Critical
Publication of JP7034162B2 publication Critical patent/JP7034162B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019533095A 2016-12-15 2017-12-14 インフルエンザウイルス複製の阻害剤及びその使用 Active JP7034162B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611158754.5 2016-12-15
CN201611158754 2016-12-15
PCT/CN2017/116154 WO2018108125A1 (en) 2016-12-15 2017-12-14 Inhibitors of influenza virus replication and uses thereof

Publications (3)

Publication Number Publication Date
JP2020513415A JP2020513415A (ja) 2020-05-14
JP2020513415A5 JP2020513415A5 (enExample) 2020-12-17
JP7034162B2 true JP7034162B2 (ja) 2022-03-11

Family

ID=62558051

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019533095A Active JP7034162B2 (ja) 2016-12-15 2017-12-14 インフルエンザウイルス複製の阻害剤及びその使用

Country Status (8)

Country Link
US (1) US10987354B2 (enExample)
EP (1) EP3555095B1 (enExample)
JP (1) JP7034162B2 (enExample)
KR (1) KR102554019B1 (enExample)
CN (1) CN108218873B (enExample)
AU (1) AU2017376541B2 (enExample)
CA (1) CA3045371C (enExample)
WO (1) WO2018108125A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180356A (es) 2015-12-15 2018-08-22 Shionogi & Co Un medicamento caracterizado por combinar un inhibidor de la endonucleasa cap-dependiente del virus de la influenza y un fármaco anti-influenza
WO2018127096A1 (en) 2017-01-05 2018-07-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
CN110446711B (zh) 2017-03-02 2022-02-15 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
CN109384783A (zh) * 2017-08-09 2019-02-26 银杏树药业(苏州)有限公司 新型杂环化合物及其作为抗流感病毒抑制剂的医药用途
CN111665297B (zh) * 2019-03-05 2024-04-26 广东东阳光药业股份有限公司 一种Baloxavir marboxil光学异构体的分离检测方法
CN110013483B (zh) * 2019-05-10 2022-04-15 江苏师范大学 噻唑并[3,2-a]嘧啶-6-甲腈衍生物用于抗菌的用途
CN110305091B (zh) * 2019-06-19 2021-05-18 江苏理工学院 一种巴洛沙韦中间体化合物的制备方法
CN114340614B (zh) * 2019-09-27 2024-01-16 广东东阳光药业股份有限公司 一种奥司他韦制剂
CN112684028B (zh) * 2020-12-04 2022-05-17 中山奕安泰医药科技有限公司 一种2-(2-氯-1-亚乙基)酰肼甲酸甲酯纯度的检测方法
CN113603693B (zh) * 2021-07-13 2022-08-26 陕西丽彩药业有限公司 一种2-溴-5-对甲苯磺酰基-5H-吡咯并[2,3-b]吡嗪的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520738A (ja) 2004-11-22 2008-06-19 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼの阻害剤として有用なピロロピラジンおよびピラゾロピラジン
JP2012530713A (ja) 2009-06-17 2012-12-06 バーテックス ファーマシューティカルズ インコーポレイテッド インフルエンザウイルス複製の阻害剤
WO2013184985A1 (en) 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP2016537347A (ja) 2013-11-13 2016-12-01 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated アザインドール化合物の製剤

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2822059A1 (en) 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2012083122A1 (en) 2010-12-16 2012-06-21 Vertex Pharmaceutical Incorporated Inhibitors of influenza viruses replication
CN103492381A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP3421468B1 (en) 2013-11-13 2020-11-04 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
JP6577570B2 (ja) 2014-08-08 2019-09-18 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー インフルエンザウイルス感染に使用するためのインドール類
DK3191489T3 (da) 2014-09-08 2021-03-29 Janssen Sciences Ireland Unlimited Co Pyrrolopyrimidiner til anvendelse ved influenzavirusinfektion
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated インフルエンザウイルスの複製の阻害剤を調製する方法
MA43298A (fr) 2015-11-27 2021-04-14 Janssen Sciences Ireland Unlimited Co Derives heterocycliques d'indole pour des infections par le virus de la influenza
EP3362451B1 (en) 2015-12-09 2023-04-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
EA201891576A1 (ru) 2016-01-07 2018-11-30 Янссен Сайенсиз Айрлэнд Юси Функционализированные пентановые кислоты для применения при инфекциях, вызванных вирусом гриппа
KR20180100375A (ko) 2016-01-20 2018-09-10 얀센 사이언시즈 아일랜드 유씨 인플루엔자 바이러스 감염에서 사용하기 위한 아릴 치환 피리미딘
WO2017133669A1 (en) 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh 5, 7-diazaindole and 5, 7-diazaindazole derivatives and their use in the treatment, amelioration or prevention of influenza
WO2017133667A1 (en) 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2017133664A1 (en) 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Bicyclic pyridine and pyrimidine derivatives and their use in the treatment, amelioration or prevention of influenza
WO2017133665A1 (en) 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh 6,7-diazaindazole and 6,7-diazaindole derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2017133658A1 (en) 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh 4, 7-diazaindole and 4, 7-diazaindazole derivatives and their use in the treatment, amelioration or prevention of influenza
WO2017133657A1 (en) 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2017133670A1 (en) 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2017198122A1 (zh) 2016-05-19 2017-11-23 四川大学 抗流感小分子化合物及其制备方法和用途
WO2018033082A1 (en) 2016-08-16 2018-02-22 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
CN109641868B (zh) 2016-08-30 2021-12-03 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
CN110623958B (zh) 2016-09-05 2022-05-17 广东众生睿创生物科技有限公司 抗流感病毒嘧啶衍生物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520738A (ja) 2004-11-22 2008-06-19 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼの阻害剤として有用なピロロピラジンおよびピラゾロピラジン
JP2012530713A (ja) 2009-06-17 2012-12-06 バーテックス ファーマシューティカルズ インコーポレイテッド インフルエンザウイルス複製の阻害剤
WO2013184985A1 (en) 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP2016537347A (ja) 2013-11-13 2016-12-01 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated アザインドール化合物の製剤

Also Published As

Publication number Publication date
EP3555095A1 (en) 2019-10-23
CN108218873A (zh) 2018-06-29
CA3045371A1 (en) 2018-06-21
KR102554019B1 (ko) 2023-07-11
KR20190092545A (ko) 2019-08-07
JP2020513415A (ja) 2020-05-14
CA3045371C (en) 2024-05-14
US20200085822A1 (en) 2020-03-19
AU2017376541B2 (en) 2021-08-05
WO2018108125A1 (en) 2018-06-21
US10987354B2 (en) 2021-04-27
EP3555095A4 (en) 2020-07-01
EP3555095B1 (en) 2023-04-12
AU2017376541A1 (en) 2019-06-13
CN108218873B (zh) 2020-07-07

Similar Documents

Publication Publication Date Title
US11225477B2 (en) Inhibitors of influenza virus replication, application methods and uses thereof
JP7034162B2 (ja) インフルエンザウイルス複製の阻害剤及びその使用
US10647693B2 (en) Inhibitors of influenza virus replication, application methods and uses thereof
US10501444B2 (en) Inhibitors of influenza virus replication, application methods and uses thereof
US11098042B2 (en) Inhibitors of influenza virus replication and uses thereof
CN108727369B (zh) 流感病毒复制抑制剂及其用途
US10927118B2 (en) Inhibitors of influenza virus replication and uses thereof
CN110117285B (zh) 流感病毒复制抑制剂及其用途
HK40011744B (en) Inhibitors of influenza virus replication and uses thereof
HK40011744A (en) Inhibitors of influenza virus replication and uses thereof
HK1254668B (en) Inhibitors of influenza virus replication, application methods and uses thereof
HK40002434A (en) Inhibitors of influenza virus replication, application methods and uses thereof

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20191107

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20191112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201102

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20201106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220301

R150 Certificate of patent or registration of utility model

Ref document number: 7034162

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250